Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Small Pharma Inc (OP:DMTTF)

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Small Pharma Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Small Pharma Reports Fiscal First Quarter 2024 Highlights
From Small Pharma Inc.
Via GlobeNewswire
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic... 
Via Benzinga
Small Pharma Implements Costs Cut: New R&D Strategy And Management Team Change
Together with reporting its annual financial results and pipeline update, short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) stated its intentions to 
Via Benzinga
Small Pharma Announces SPL028 R&D Strategy Update
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Announces Management Team Change
From Small Pharma Inc.
Via GlobeNewswire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
Small Pharma Implements Cost-Cutting Strategy To Reduce Cash Burn As Trial Progresses
UK-based biotech firm Small Pharma Inc. (OTCQB: DMTTF) shared its financial outcomes for the fiscal year ended Feb. 28, plus pipeline updates.  Highlights: 
Via Benzinga
Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
From Small Pharma Inc.
Via GlobeNewswire
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
Via Benzinga
Small Pharma's IP Portfolio Grows With Numerous Approved Patent Applications Around The World
U.K.-based short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) has been working hard on securing a proprietary IP throughout North America, Australasia and Europe. 
Via Benzinga
Small Pharma Announces Significant Developments In Intellectual Property Portfolio
5 new patent grants, 3 expected upcoming patent grants, and 8 notices of allowance in key international jurisdictions 
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
Chief Medical and Scientific Officer, Dr. Carol Routledge, will deliver a poster presentation on data from the Company’s SPL026 Phase IIa clinical trial in patients with Major Depressive Disorder 
From Small Pharma Inc.
Via GlobeNewswire
DMT For Major Depression Shows Remarkable Benefits After Six-Month Trial
Short-acting psychedelics company Small Pharma Inc. 
Via Benzinga
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-months 
From Small Pharma Inc.
Via GlobeNewswire
EXCLUSIVE: NYC Ketamine Center Co-Founder On Prices, Insurance, Competition & Expansion
This is the third article of a three-part series, you can find the first and 
Via Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
Via Benzinga
Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll... 
Via Benzinga
Small Pharma Inc: Positive Clinical Data For Major Depressive Disorder, Upcoming Virtual Roundtable
Short-acting psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) shared positive outcomes from its Phase 2a study of SPL026, the first placebo-controlled trial of the DMT-based short-duration... 
Via Benzinga
Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference
Company will also host a cocktail reception on Tuesday, March 7 
From Small Pharma Inc.
Via GlobeNewswire
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
Short-Acting Psychedelics: DMT-Based Drug Therapy Gets Tested In New Clinical Trial
Psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) has dosed the first subject in its first-in-human clinical trial assessing proprietary DMT drug SPL028 paired with supportive therapy. 
Via Benzinga
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
From Small Pharma Inc.
Via GlobeNewswire
Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents
After the positive results provided by its clinical trial assessing novel DMT’s effects on patients with Major Depressive Disorder (MDD), psychedelics biotech Small Pharma Inc. 
Via Benzinga
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings
Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF)’s proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major... 
Via Benzinga
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental 
Via PressReach
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
From Small Pharma Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback